ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock News

USA - NASDAQ:ARQT - US03969K1088 - Common Stock

20.88 USD

-0.03 (-0.14%)

Last: 10/17/2025, 8:00:01 PM

20.96 USD

+0.08 (+0.38%)

After Hours: 10/17/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ARQT Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Arcutis Biotherapeutics, Inc.

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

12 days ago - By: Arcutis Biotherapeutics, Inc.

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

14 days ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17 days ago - By: Zacks Investment Research

Arcutis Biotherapeutics, Inc. (ARQT) Hit a 52 Week High, Can the Run Continue?

2 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis to Present at Upcoming Investor Conferences

2 months ago - By: The Motley Fool

Arcutis (ARQT) Q2 Revenue Soars 164%

2 months ago - By: Benzinga - Mentions: OEC VTLE DIN INSE ...

Earnings Scheduled For August 6, 2025

18 days ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025

18 days ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025

a month ago - By: Arcutis Biotherapeutics, Inc.

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

a month ago - By: Arcutis Biotherapeutics, Inc.

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

a month ago - By: Arcutis Biotherapeutics, Inc.

Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award

a month ago - By: Arcutis Biotherapeutics, Inc.

Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award

a month ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

a month ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

a month ago - By: Palvella Therapeutics Inc. - Mentions: PVLA

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

2 months ago - By: Zacks Investment Research

Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?

2 months ago - By: Benzinga - Mentions: SPY ADCT QQQ CLLS ...

Top 5 Biotech Stocks With Strong Momentum

2 months ago - By: Zacks Investment Research - Mentions: FHTX

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

2 months ago - By: Zacks Investment Research

Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know

2 months ago - By: Zacks Investment Research - Mentions: THC

Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?

2 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Zacks Investment Research - Mentions: RNA

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates

2 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

2 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

4 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

4 months ago - By: Yahoo Finance - Mentions: VZ AMZN WMT CADE ...

How Cadence Bank, Kimberly-Clark, And Robert Half Can Put Cash In Your Pocket

4 months ago - By: Yahoo Finance - Mentions: UBS KR UNP DE ...

UBS Maintains Neutral on Kroger Ahead of Earnings, Sees Balanced Risk-Reward Outlook

4 months ago - By: Yahoo Finance - Mentions: BLND SNY NVDA TSM ...

Covius Services to Acquire Blend Labs’ (BLND) Title365 Holding Co

4 months ago - By: Yahoo Finance - Mentions: ELV ACGL AGIO AZN ...

Truist Lowers Elevance Health (ELV) to $500, Keeps Buy Rating

4 months ago - By: Yahoo Finance - Mentions: SPRY MEOH GSC KR ...

Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”

4 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis